Novo Nordisk A/ S stock (DK0060534915): Diabetes and obesity leader with global reach

Novo Nordisk A/S continues to lead the global market for diabetes and obesity treatments, powered by its GLP-1 receptor agonists such as Ozempic and Wegovy. The company reported robust sales growth in its latest full-year results for 2025, published March 5, 2026, with international revenue reaching DKK 290.4 billion, up 25% at constant exchange rates, according to Novo Nordisk Annual Report as of March 5, 2026. This performance underscores its critical role in addressing the growing obesity epidemic, particularly relevant for US investors given the company's significant exposure to the American healthcare market.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Novo Nordisk A/S: core business model

Novo Nordisk A/S focuses on discovering, developing, and delivering innovative treatments for serious chronic diseases, with a primary emphasis on diabetes and obesity care. Founded in 1923, the company has built a portfolio centered on insulin therapies and, more recently, GLP-1 agonists that mimic hormones to regulate blood sugar and appetite. Its business model relies on high-margin pharmaceuticals sold globally through partnerships with healthcare providers and pharmacies. In 2025, diabetes and obesity care accounted for 89% of net sales, highlighting its specialized focus, as detailed in the 2025 Annual Report as of March 5, 2026.

The company's vertical integration includes manufacturing facilities in Denmark, the US, and other regions, ensuring supply chain control amid surging demand for weight-loss drugs. Novo Nordisk invests heavily in R&D, spending DKK 29.3 billion in 2025, or 10% of sales, to expand its pipeline in cardiovascular and rare diseases. This model positions it as a leader in a market projected to grow significantly, with US sales contributing over 50% of total revenue.

Main revenue and product drivers for Novo Nordisk A/S

Ozempic, approved for type 2 diabetes, and Wegovy, for chronic weight management, are the primary revenue engines. Wegovy sales soared 86% in 2025 to DKK 95.6 billion, driven by expanding indications and patient uptake in the US, where obesity affects over 40% of adults. Ozempic added DKK 112.1 billion, up 46%, per the annual report cited above. These GLP-1 products benefit from weekly dosing and strong efficacy data, fueling repeat prescriptions.

Insulin products like Tresiba and NovoLog remain steady contributors, generating DKK 42.7 billion in 2025, while newer areas like rare diseases (Voxzogo) grew 117%. US market dominance is evident, with North American sales at DKK 155.4 billion, up 37%, making Novo Nordisk a key player for US investors tracking healthcare innovation.

Industry trends and competitive position

The diabetes and obesity sector is expanding rapidly due to aging populations and lifestyle factors, with the global obesity market expected to reach $100 billion by 2030. Novo Nordisk holds about 55% of the GLP-1 market share, ahead of Eli Lilly's Mounjaro/Zepbound, thanks to earlier market entry and manufacturing scale. Supply constraints have eased with new US facilities online in 2025, supporting growth.

Competition intensifies from biosimilars and oral GLP-1s like Lilly's orforglipron in trials. However, Novo Nordisk's CagriSema, a combo drug, showed 22.7% weight loss in phase 3 trials reported December 2025, per company releases, bolstering its edge. For US investors, the company's NYSE ADR listing (NVO) provides easy access to this high-growth story.

Why Novo Nordisk A/S matters for US investors

Novo Nordisk's heavy US reliance—over half its revenue—ties it directly to American healthcare spending and obesity trends. The NYSE-listed ADR (NVO) trades in USD, appealing to retail investors seeking exposure to pharma without currency risk. Recent expansions, including a $4.1 billion Clayton, NC plant opened in 2024, create US jobs and secure supply, as noted in company press releases as of June 2024.

Policies like Medicare coverage for weight-loss drugs could further boost sales, given 100 million obese US adults. This positions Novo Nordisk as a staple in US portfolios focused on defensive growth sectors.

Conclusion

Novo Nordisk A/S stands out as a pharmaceutical powerhouse with unmatched leadership in diabetes and obesity care, driven by blockbuster GLP-1 drugs and a robust pipeline. Its strong 2025 financials and US market exposure highlight resilience amid industry growth. Investors monitoring healthcare trends will note its competitive moat and expansion efforts, though sector rivalry persists.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.